AMBS up Wed 22% Thrus 160% Friday 32% Monday 95%! News is out.
Since when is sharing an idea with fellow investors "invading"? I'm glad you typed it in all caps like that though I might have not seen your message if you hadn't. AMBS closed up another 25% today and since Halloween over 700% don't you invest in more than one stock? I'd love it if PSTI were blowing up on some good news and you "invaded" my board on any number of stocks I follow and said hey this things on fire check them out. No shame in my game no matter how large you type your letters.
But you see vomitindicator1 (nice name) wanted to find a couple of smart people like yourselves who "know where the caps lock is" to help me understand exactly what the co founder of Amgen is talking about in the second paragraph;
SUNNYVALE, Calif., Nov. 6, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it has appointed Amgen Co-Founder Joseph Rubinfeld, PhD to its Corporate Advisory Board. Dr. Rubinfeld will assist management in positioning the Company's development programs for partnering, as well as provide guidance on MANF-based small molecule strategies with his extensive medicinal chemistry background.
"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."